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Up to 70% of patients with cancer will develop spine
metastasis. Clinical presentations vary, but pain, instability,
and neurologic deﬁcit alone or in combination are usually
manifested. General management options include analgesia
or more comprehensive palliative care pathways, hormonal
or chemotherapy, radiation therapy, and surgery. Metastatic
patients are unique compared to patients in other domains
of health care. For the most part, these patients cannot be
cured and are on a palliative trail of uncertain duration
and quality of life. Decisions around care in this patient
population must be shared with the patient, loved ones, and
a multidisciplinary team knowledgeable in the spectrum of
interventions available and the evidence on which they are
founded.
Because of the multitude of issues involved in these
patients’ treatment decision making is diﬃcult and contro-
versial and must be individualized. Several scoring systems
orclassiﬁcationshavebeendevelopedoverthepast2decades
to help guide physicians in making the right treatment
choices for their patients. Although no one classiﬁcation
is comprehensive enough or has gone through exhaustive
psychometric analysis, they do help guide physicians in
determining some treatment options. Often they are based
on life expectancy, general health or imaging parameters and
not on the primary clinical outcome of interest—health-
related quality of life (HRQOL). Although HRQOL has
broad and varying deﬁnitions depending on what aspect you
are focussing on, treatment of patients with spine metastases
shouldbedirectedtoimprovinggenericHRQOLoraspeciﬁc
aspect of it, such as pain. Recently there has been a growth in
HRQOL research in patients with spine metastases and this
has helped direct treatment.
Another area of rapid growth has been in technology in
both the radiation and surgical domains. Stereotactic radio-
surgery, percutaneous vertebral augmentation, and mini-
mally invasive surgery have added to the physician and sur-
geon’s armamentarium. Where they stand in comparison to
more conventional forms of treatment has not been clearly
determined, but their impact on HRQOL has certainly been
positive. The real challenge now lies in the development of
a new paradigm in the management of spine metastases
as new technology has expanded indications and provided
potentially more options to improve HRQOL.
In this special issue, we have invited seven papers that
providethemostup-to-dateandcomprehensiveinformation
about the management of patients with spine metastases.
Essential background has been provided by G. Maccauroand
colleagues with a detailed and clear paper on physiopathol-
ogy of spine metastasis, underlining the aspects related to
epidemiology, pathogenesis, and prognosis. An exhaustive
reference list guides the reader to a deeper knowledge on the
issue.
L. M. Shah and K. L. Salzman have described the state of
the art of imaging in spinal metastatic disease, underlining
the role of new technology and innovation through CT,
MRI and nuclear medicine such as FDG-PET/CT. Imaging
actually plays a fundamental role in not only diagnosis but
also treatment planning and is part of the multidisciplinary
approach to the issue.2 International Journal of Surgical Oncology
Metastatic tumors of the spine can be either intradural
orextradural.Intramedullaryspinalcordmetastasesareeven
rarer than bone spine malignancies. Optimal management is
diﬃcult to identify due to the variety of clinical situations
and the lack of controlled studies. O. Kalita and colleagues
show a review of the literature on this topic.
W. A. Hall and colleagues wrote an evidence-based
review on stereotactic body radiosurgery that is emerging as
an eﬀective and safe treatment modality for spinal tumors,
both primary and metastatic. C. A. Molina, P. S. Rose and J.
H. Schwab report about the minimally invasive spine surgery
(MISS). The ﬁrst of them has performed a systematic review
of the actual role of the procedure in the setting of spine
metastases management. P. S. Rose and colleagues describe
the surgical techniques used and possible combination with
otherprocedurestogainthebestpossibleresult.J.H.Schwab
deals with outcome evaluation in patients aﬀected by spine
metastases and treated with MISS. Good preliminary results
reported are in favour of these techniques, but authors also
underline the need for a multidisciplinary approach and a
careful evaluation of the surgical indication.
In conclusion a global, contextualized, multidisciplinary
approach to spinal metastases is essential if optimal HRQOL
is to be achieved [1]. Furthermore, we must encourage and
evaluate new technology so as to expand the options for this
challenging and very deserving patient population.
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